Retatrutide: Phase 3 results do not yet equal an approval
Retatrutide, also known as LY3437943, combines GIP, GLP-1 and glucagon receptor agonism.
Retatrutide, also known as LY3437943, combines GIP, GLP-1 and glucagon receptor agonism. Lilly continues to describe it as investigational. Its story has advanced beyond early proof of concept: the company announced Phase 3 TRIUMPH-1 results in May 2026 and additional TRIUMPH results in July. These are sponsor-reported findings, not an FDA decision. Lilly program account, May readout, July readouts.
The TRIUMPH-1 record includes weight change at 80 weeks and additional assessments in sleep-apnea and osteoarthritis subsets, with longer follow-up for an extension subset. Different populations and follow-up periods are separate evidence questions. The study is recorded as completed in the retrieved snapshot. NCT05929066.
The useful competitive question is whether the expanded mechanism produces a favorable balance of sustained weight effects, tolerability and other outcomes in defined populations. It cannot be answered by ranking headline percentages from unlike trials. The cardiovascular estimate in Lilly's July release had an uncertainty interval crossing no difference; this account therefore makes no claim of proven cardiovascular risk reduction.
Lilly said in its July release that it planned a US submission in the first quarter of 2027. That target is separate from an application actually submitted, accepted or approved; future accounts should preserve those distinctions. Lilly's financial context (below) supports assessment of execution resources, without treating a large parent's finances as evidence of clinical success.
Eli Lilly — company resources
Lilly reported $8.950 billion of cash and equivalents at June 30. Short-term borrowing and current debt totaled $7.050 billion, with $47.858 billion of long-term debt. First-half operating cash generation was $16.023 billion and net income $14.491 billion. Its investment portfolio includes venture and private investments, which should not all be added to cash as immediately available liquidity. The corporate cash-generation base supports a broad development and manufacturing program; the accounts do not allocate these balances to any individual compound discussed here. Form 10-Q filed August 5.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment.